Survival and prognostic factors in patients treated with stereotactic radiotherapy for brain metastases

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Abstract

Abstract Background. Stereotactic radiation therapy (SRT) of brain metastases is used with good effect around the world, but no consensus exists regarding which prognostic factors that are related to favourable or unfavourable prognosis after the treatment. A better definition of these factors will ensure a more precise application of the treatment. Material and methods. A consecutive cohort of the 198 patients treated for brain metastases with SRT without concurrent whole-brain radiation therapy at our department from 2001 to 2012 was retrospectively analysed. Results. Median survival was seven months and median time to clinical cerebral progression was eight months. The multivariate analysis revealed age ≥ 65 years, Performance Status ≥ 2, extracranial metastases and size of metastasis > 20 mm as independent prognostic factors related to shorter survival. No factors were independently related to clinical cerebral progression. Conclusion. We identified four prognostic factors related to survival after SRT for brain metastases. The grouping of patients by these factors is useful to determine the level of treatment. We discourage the delivery of SRT to patients with 3-4 unfavourable prognostic factors because of the very short median survival of two months.
Original languageEnglish
JournalActa Oncologica
Volume54
Issue1
Pages (from-to)107-14
Number of pages8
ISSN0284-186X
DOIs
Publication statusPublished - Jan 2015

Fingerprint

Dive into the research topics of 'Survival and prognostic factors in patients treated with stereotactic radiotherapy for brain metastases'. Together they form a unique fingerprint.

Cite this